Literature DB >> 32513684

Evidence generation, decision making, and consequent growth in health disparities.

Anirban Basu1,2, Kritee Gujral3.   

Abstract

Evidence is valuable because it informs decisions to produce better outcomes. However, the same evidence that is complete for some individuals or groups may be incomplete for others, leading to inefficiencies in decision making and growth in disparities in outcomes. Specifically, the presence of treatment effect heterogeneity across some measure of baseline risk, and noisy information about such heterogeneity, can induce self-selection into randomized clinical trials (RCTs) by patients with distributions of baseline risk different from that of the target population. Consequently, average results from RCTs can disproportionately affect the treatment choices of patients with different baseline risks. Using economic models for these sequential processes of RCT enrollment, information generation, and the resulting treatment choice decisions, we show that the dynamic consequences of such information flow and behaviors may lead to growth in disparities in health outcomes across racial and ethnic categories. These disparities arise due to either the differential distribution of risk across those categories at the time RCT results are reported or the different rate of change of baseline risk over time across race and ethnicity, even though the distribution of risk within the RCT matched that of the target population when the RCT was conducted. We provide evidence on how these phenomena may have contributed to the growth in racial disparity in diabetes incidence.

Entities:  

Keywords:  diabetes incidence; evidence-based medicine; health disparity; treatment effect heterogeneity

Year:  2020        PMID: 32513684      PMCID: PMC7321972          DOI: 10.1073/pnas.1920197117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

1.  The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group.

Authors: 
Journal:  Diabetes Care       Date:  2000-11       Impact factor: 19.112

2.  The prevention or delay of type 2 diabetes.

Authors:  Robert S Sherwin; Robert M Anderson; John B Buse; Marshall H Chin; David Eddy; Judith Fradkin; Theodore G Ganiats; Henry Ginsberg; Richard Kahn; Robin Nwankwo; Marion Rewers; Leonard Schlessinger; Michael Stern; Frank Vinicor; Bernard Zinman
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

3.  Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.

Authors:  Richard L Kravitz; Naihua Duan; Joel Braslow
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

4.  The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

5.  Welfare implications of learning through solicitation versus diversification in health care.

Authors:  Anirban Basu
Journal:  J Health Econ       Date:  2015-04-20       Impact factor: 3.883

6.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

7.  Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012.

Authors:  Linda S Geiss; Jing Wang; Yiling J Cheng; Theodore J Thompson; Lawrence Barker; Yanfeng Li; Ann L Albright; Edward W Gregg
Journal:  JAMA       Date:  2014-09-24       Impact factor: 56.272

8.  Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.

Authors:  David M Kent; Jason Nelson; Issa J Dahabreh; Peter M Rothwell; Douglas G Altman; Rodney A Hayward
Journal:  Int J Epidemiol       Date:  2016-12-01       Impact factor: 7.196

9.  A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC's National Diabetes Prevention Program.

Authors:  Elizabeth K Ely; Stephanie M Gruss; Elizabeth T Luman; Edward W Gregg; Mohammed K Ali; Kunthea Nhim; Deborah B Rolka; Ann L Albright
Journal:  Diabetes Care       Date:  2017-05-12       Impact factor: 19.112

10.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement.

Authors:  David M Kent; Jessica K Paulus; David van Klaveren; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.